Skip to main content
. 2010 Feb;5(2):299–306. doi: 10.2215/CJN.07131009

Table 1.

Baseline subject characteristics by treatment group

Characteristics Cholecalciferol (n = 22) Doxercalciferol (n = 25) P
CKD, n 0.51
    Stage 3 12 16
    Stage 4 10 19
Gender, n 0.20
    Female 12 9
    Male 10 16
Race, n 0.20
    African American 166 12
    White 6 13
Cause of CKD, diabetes/hypertension/other causes, % 36/40/24 50/31/18
Age, yr 62 ± 10 65 ± 10 0.31
Years of CKD 4.2 ± 2.6 3.9 ± 2.7 0.73
GFR (MDRD) 29.6 ± 7.4 36.4 ± 10.7 0.02
Creatinine, mg/dl 2.56 ± 0.83 2.19 ± 0.50 0.08
BMI 34.8 ± 5.9 35.9 ± 8.6 0.60
Albumin, mg/dl 4.7 ± 0.5 4.7 ± 0.5 0.85

BMI, body mass index.